Rezolute, Inc.
(NASDAQ : RZLT)

( )
RZLT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.20%182.140.7%$1408.62m
MRKMerck & Co., Inc. -0.21%93.080.7%$1238.86m
PFEPfizer Inc. -0.17%51.610.9%$1232.04m
BMYBristol-Myers Squibb Co. -0.17%78.861.0%$1135.54m
LLYEli Lilly & Co. -0.10%325.351.1%$1134.85m
ABBVAbbVie, Inc. 0.22%152.881.9%$1021.46m
AZNAstraZeneca Plc -0.72%66.421.0%$448.85m
SGENSeagen Inc. -1.61%176.455.7%$320.77m
GSKGSK Plc -0.46%43.490.2%$296.07m
TPTXTurning Point Therapeutics, Inc. 0.00%75.170.0%$291.93m
MRTXMirati Therapeutics, Inc. 2.70%70.001.6%$204.79m
SIGASIGA Technologies, Inc. -11.50%11.540.0%$194.41m
HZNPHorizon Therapeutics Plc 0.00%85.135.4%$182.59m
NVSNovartis AG -0.04%84.790.2%$167.69m
NVONovo Nordisk A/S 0.58%112.820.1%$148.21m

Company Profile

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio includes RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.